1,500 Shares in Celgene Co. (CELG) Purchased by Shikiar Asset Management Inc.
Shikiar Asset Management Inc. bought a new stake in Celgene Co. (NASDAQ:CELG) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,500 shares of the biopharmaceutical company’s stock, valued at approximately $219,000.
Other hedge funds also recently bought and sold shares of the company. Neuberger Berman Group LLC lifted its holdings in shares of Celgene by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after purchasing an additional 71,729 shares in the last quarter. Grisanti Capital Management LLC bought a new position in shares of Celgene in the second quarter valued at approximately $3,616,000. Lincoln Capital Corp lifted its holdings in shares of Celgene by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares in the last quarter. RiverPoint Capital Management LLC lifted its holdings in shares of Celgene by 3.1% in the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after purchasing an additional 3,680 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Celgene by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after purchasing an additional 54,210 shares in the last quarter. Institutional investors own 80.16% of the company’s stock.
A number of research analysts have recently weighed in on CELG shares. BMO Capital Markets raised their target price on Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, November 17th. Oppenheimer reiterated a “buy” rating and set a $170.00 price target on shares of Celgene in a report on Friday, October 20th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a report on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene in a report on Thursday, October 26th. Finally, Morgan Stanley upgraded Celgene from an “underweight” rating to an “equal weight” rating in a report on Friday, October 27th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $136.21.
In other news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.95% of the stock is currently owned by insiders.
Celgene Co. (NASDAQ:CELG) opened at $109.41 on Friday. The firm has a market capitalization of $86,140.36, a price-to-earnings ratio of 17.10, a PEG ratio of 0.84 and a beta of 1.78. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.58 earnings per share. analysts anticipate that Celgene Co. will post 6.68 EPS for the current year.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with Analyst Ratings Network's FREE daily email newsletter.